.png){kind=logo}
US-based sterile injectable (pre-filled syringe) manufacturing facility focused on small-molecule generic 505b2 and 505j products.
Minimally-invasive nitinol implant delivered into prostatic urethra and indicated to re-open the prostatic urethra in BPH patients, restoring urinary flow.
HOW WE USE YOUR INFORMATION
-
to operate, manage, develop and promote our business and, in particular, our relationship with you and the organization you represent (if any) and related investments and/or transactions;
-
to operate, administer and improve our website and premises and other aspects of the way in which we conduct our operations;
-
to protect our business from fraud, money-laundering, breach of confidence, theft of proprietary materials and other financial or business crimes;
-
to send marketing communications to you, if applicable and
-
to comply with our legal and regulatory obligations and bring and defend legal claims.
​
We may review information about you that we maintain in our systems, including the contents of and information related to your emails and other communications with us, for compliance and business-protection purposes as described above. This may include reviews to disclose information relevant to litigation and/or reviews of records relevant to internal or external regulatory or criminal investigations. To the extent permitted by applicable law, these reviews will be conducted in a reasonable and proportionate way and approved at an appropriate level of management. They may ultimately involve the disclosure of your information to governmental agencies and litigation counterparties as described below. Your emails and other communications may occasionally be accessed by persons other than the staff member with whom they are exchanged for ordinary business management purposes (for example, where necessary when a staff member is out of the office or has left New Rhein). 
​
We will only use your personal information for the purposes for which we collected it, unless we reasonably consider that we need to use it for another reason and that reason is compatible with the original purpose. If you wish to get an explanation as to how the processing for the new purpose is compatible with the original purpose, please contact us.
​
If we need to use your personal information for an unrelated purpose, we will notify you and we will explain the legal basis which allows us to do so.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
Greg Parekh, PhD
Founder & Managing Partner
Greg Parekh is the founder and a Managing Partner of New Rhein. Before launching New Rhein, Greg led the integration planning for Alcon on behalf of Novartis AG, where he previously ran the Mergers & Acquisitions group from 2004 to 2009. During his time at Novartis, Greg helped execute over 20 transactions with a total deal value of more than $70 billion. Prior to joining Novartis, Greg headed Deutsche Bank’s European Healthcare Group from 1998 to 2004. Greg joined Deutsche Bank from Bear Stearns in New York, where he started his career in 1995 as an associate in the Life Sciences group.
Greg has served as a director of the companies in which New Rhein made it initial deal-by-deal investments, Novagali Pharma, SA (a Paris, France based ophthalmology company), Chase Pharmaceuticals, a U.S. Alzheimer’s drug company, and Biocartis NV, a Belgian oncology diagnostics company, for which Greg also served as Chief Executive Officer from 2011 to 2013. Greg presently serves on the boards of Fund 18 portfolio companies, Softhale NV and Neuraptive Therapeutics, Inc., Butterfly Medical Ltd. and is a director of Cancerlinq, a big-data digital healthcare platform and wholly owned subsidiary of the American Society of Clinical Oncology (ASCO). Greg holds a Ph.D. in Economics from Northwestern University, an executive leadership program certificate from Harvard Business School and a dual-major B.A. from University of Rochester (magna cum laude). Greg's hobbies include gourmet cooking, downhill skiing and music.